Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic has concluded patient enrollment in its Connect trial, which is assessing how the use of the Medtronic CareLink Network to remotely monitor patients with the Concerto cardiac resynchronization therapy-defibrillator and Virtuoso implantable cardioverter-defibrillator effectively enables better patient care and reduces unnecessary healthcare costs.
Subscribe to our email newsletter
Connect is a randomized, prospective study that includes 2,000 patients at 141 centers across the US and the patients will be followed for 15 months. The primary objective of Connect trial is to demonstrate that Medtronic’s wireless remote management system reduces the time to clinical decision for arrhythmias, cardiovascular disease progression, and system issues compared to patients who receive only in-office care.
Secondary objectives include a reduction in healthcare utilization, such as hospitalizations and visits to the emergency room, and characterizing the burden of in-office follow up visits for patients and their families, among other patient quality of life issues.
George Crossley, chief of electrophysiology at Baptist Hospital and Mid-State Cardiology in Nashville, Tennessee, said: “Now that enrollment in the Connect trial is complete, we’re looking forward to seeing the data, which we believe will bear out that early indication of worsening heart conditions leads to early interventions, preventing costly hospitalizations.”